Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Raises Additional $9M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Direct-to-consumer genomics firm 23andMe today announced it has raised an additional $9 million in its Series C financing round, bringing the total funding in the round to $31 million.

MPM Capital joined Johnson & Johnson Development Corp. as a new investor, the Mountain View, Calif.-based firm said. Ashley Ledbetter Dombkowski, a director at MPM, is joining 23andMe's board, it added.

In November, the company said it had raised $22 million in the round. The funding will be used to accelerate the firm's research, it added.

Along with MPM and J&J, other investors in 23andMe include Roche Venture Fund, Google Ventures, and New Enterprise Associates.

In a statement, 23andMe CEO Anne Wojcicki said the firm "has aligned a powerful constellation of expertise in strategic healthcare, healthcare venture funding, consumer markets, information technology, and business strategy that will enable us to bring the vision of personalized medicine to consumers faster."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more